Pharmacy & Therapeutics Committee
The ConnectiCare Drug List is overseen by the Pharmacy and Therapeutics (P&T) Committee. This committee is responsible for overseeing drug utilization and quality drug therapy including the ConnectiCare drug formulary.
The P&T Committee is comprised of primary care and specialty physicians and community pharmacists who participate with ConnectiCare's Chief Medical Officer, the VP of Pharmacy Solutions, Director of Pharmacy Operations, and clinical pharmacists. The role of the P&T Committee is to provide advice and/or consent regarding the development, review, and revision of ConnectiCare's pharmaceutical management procedures. In addition, the Committee performs regular review of new drugs and drug classes to determine placement on the formulary.
The P&T Committee meets quarterly, or as needed, and functions as a subcommittee of ConnectiCare's Quality Management Committee.
Product Selection Criteria
The P&T Committee examines objective characteristics of an individual drug during its evaluation for tier placement on the ConnectiCare drug list, as well as during its periodic examination of entire therapeutic drug classes.
When a new drug is considered for addition to the list, the committee consults medical literature and expert medical opinion relative to other similar drugs currently on the list, particularly with regard to the following:
- comparison studies
- approved indications
- adverse effects
- patient compliance considerations
- medical outcome and pharmacoeconomic studies
Entire therapeutic classes are reviewed at least annually in an effort to continually promote the most clinically useful and cost-effective agents in a particular therapeutic class. All drugs are covered except for a small number specifically excluded by benefit design. Some drugs require preauthorization or step therapy designated by the P&T Committee.